Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$4.08 USD
-0.11 (-2.51%)
Updated May 28, 2024 04:00 PM ET
After-Market: $4.08 +0.01 (0.12%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Rapt Therapeutics [RAPT]
Reports for Purchase
Showing records 41 - 60 ( 74 total )
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21 - Derisking Upcoming Readouts Should Make RAPT an Attractive Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
1Q21 - Derisking Upcoming Readouts Should Make RAPT an Attractive Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Reminder to Join Our KOL Call on Atopic Dermatitis Tomorrow at 10am ET
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Dermatitis Data Expected in 1H21 - KOL Call on May 6th to Discuss Hurdle
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
AACR Data Highlights RAPT''s Broad Pipeline Potential
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Enrollment Complete in Phase 1b Atopic Dermatitis Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
4Q20 Update - Readouts Reaffirmed, 2021 Could Be a Major Year for RAPT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
2020 Financials Reported; Raising PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FLX475 Remains Promising - RPT193 Data Expected in 1H2021. Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FLX475 Underwhelms; 3Q20 Financials Reported; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Register For Week-1 of Our Management Talk Series With IVA, RAPT, KALV - AGTC
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z